Michael Bigham - Mar 15, 2022 Form 4 Insider Report for Paratek Pharmaceuticals, Inc. (PRTK)

Role: Exec. Chairman of the Board, Director
Signature: /s/ William M. Haskel, Attorney-in-Fact for Michael Bigham
Stock symbol: PRTK
Transactions as of: Mar 15, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/23/2022, 08:28 PM
Previous filing: Dec 15, 2021
Next filing: Aug 10, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRTK	Common Stock	Award	$0	+203K	+22.73%	$0.00	1.09M	Mar 15, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 15/45 of the shares subject to the restricted stock units on December 10, 2022, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date.

Content

Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 15/45 of the shares subject to the restricted stock units on December 10, 2022, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date.